Skip to search formSkip to main contentSkip to account menu

brivanib alaninate

The alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

BMS 582664
Receptor Tyrosine Kinase Inhibition

Broader (1)

brivanib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma
Rationale: Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related death worldwide. Its poor… 
2015
2015
Role of Self-Association and Supersaturation in Oral Absorption of a Poorly Soluble Weakly Basic Drug
Precipitation of weakly basic drugs in intestinal fluids can affect oral drug absorption. In this study, the implications of self… 
2012
2012
Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic…
3504 Background: The anti-EGFR monoclonal antibody CET has improved survival in pts with chemotherapy refractory, K-RAS WT mCRC… 
2012
2012
Quality of life (QoL) assessment in patients (pts) with K-RAS wild-type (WT) chemotherapy refractory metastatic colorectal cancer (mCRC) treated with cetuximab (CET) plus brivanib alaninate (BRIV) or…
542 Background: The CO.20 trial randomized pts with K-RAS WT chemotherapy refractory mCRC to receive CET + BRIV (Arm A) or CET… 
2011
2011
A phase III study of cetuximab (CET) plus either brivanib alaninate (BRIV) versus placebo in patients with chemotherapy-refractory KRAS wild-type (WT) advanced colorectal cancer (aCRC): The NCIC CTG…
TPS163 Background: While anti-EGFR monoclonal antibody, CET, improves survival in KRAS WT chemotherapy refractory aCRC, dual… 
2011
2011
POLAROGRAPHIC STUDY OF MIXED LIGAND (CARBOXYMETHYLMERCAPTOSUCCINATE-ALANINATE OR ASPARTATE OR GLUTAMINATE OR VALINATE WITH CADMIUM (II) LEAD (II) AND THALLIUM (I) IN AQUEOUS ETHANOL MEDIA.
Mixed ligand systems (carboxymethylmercaptosuccinate – alaninate, carboxymethyl-mercaptosuccinate-aspartate… 
2008
2008
Correlation of FGF2 tumor expression with tumor response, PFS, and changes in plasma pharmacodynamic (PD) markers following treatment with brivanib alaninate, an oral dual inhibitor of VEGFR and FGFR…
3506 Background: Many tumors express the FGFR ligand FGF2, and increased levels of FGF are correlated with poor prognosis in pts… 
2007
2007
A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: Safety, pharmacokinetic (PK…
3559 Background: Brivanib is an oral prodrug of BMS-540215, a dual tyrosine kinase inhibitor of VEGFR and FGFR signaling. Part A… 
2006
2006
Largest discrete supramolecular architecture based on a lanthanide ion: [lanthanum(III)18{N,N'-bis(2-pyridylmethyl)-N,N'-1,2-ethanediylbis(D-alaninate)}18(H2O)36]18+.
The largest discrete octadecameric architecture based on a lanthanide ion has been found in the crystal structure of a La{N,N… 
Highly Cited
2005
Highly Cited
2005
Spontaneously formed vesicles of sodium N-(11-acrylamidoundecanoyl)-glycinate and L-alaninate in water.
Two N-acyl amino acid surfactants, sodium N-(11-acrylamidoundecanoyl)-glycinate (SAUG) and L-alaninate (SAUA), were synthesized… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)